Puridify completes Series A funding of £2.2m

Published: 22-Oct-2015

Will be used to commercialise FibroSelect single-use nanofibre-based purification technology


Puridify, a UK developer of bioprocessing purification technologies, has closed a £2.2m Series A funding round.

This Series A funding by existing investors Imperial Innovations, SR One and UCL Business, brings the total raised including grant funding to £8m.

The funds will be used to commercialise Puridify's proprietary nanofibre purification platform, FibroSelect.

The company aims to have GMP-compatible purification units ready for wider industry use during 2016.

'We are delighted that our investors and Innovate UK are continuing to support us as we look to further expand our team and focus on generating industry relevant end-user data for FibroSelect, while rapidly establishing a manufacturing basis for GMP-compliant products,' said Dr Oliver Hardick, Chief Executive of Puridify.

'Our single-use purification units will enable this technology to effectively service the wider life sciences industry. Specifically, collaborations with biotherapeutic drug manufacturers are already proving the benefit of FibroSelect as a single-use high productivity product capture platform, suitable for existing and emergent biologic therapies.'

Dr Inga Deakin, Associate, Healthcare Ventures, Imperial Innovations, added: 'Puridify is well on the way to demonstrating the potential for its nanofibre technology to make a significant impact in biologics manufacturing. The FibroSelect purification platform is ideally suited to support the industry’s increasing interest in single use and demand for smaller, more flexible manufacturing facilities that can produce multiple products.'

Puridify was formed in 2013 as a spin-out from University College London. Its FibroSelect technology was developed during a collaborative research project between the Advanced Centre for Biochemical Engineering, UCL and the Science & Technology Facilities Council.

Puridify’s head office and research & development facilities are based at the Stevenage Bioscience Catalyst.

You may also like